4.5 Review

Cannabinoids in movement disorders

期刊

PARKINSONISM & RELATED DISORDERS
卷 102, 期 -, 页码 124-130

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.parkreldis.2022.08.014

关键词

Cannabinoids; Marijuana; Parkinson?s disease; Huntington?s disease; Tourette?s syndrome

向作者/读者索取更多资源

There is growing optimism in the therapeutic potential of cannabis and cannabinoid-based chemicals for movement disorders, but scientific basis and safety concerns remain. Clinical research on cannabinoids for movement disorders shows promising results but also inconclusive or negative outcomes in some cases. Further research is needed to understand the clinical benefits and long-term side effects of medical cannabis products for movement disorders.
Introduction: On the basis of both scientific progress and popular lore, there is growing optimism in the thera-peutic potential of cannabis (marijuana) and cannabinoid-based chemicals for movement disorders. There is also notable skepticism regarding the scientific basis for this therapeutic optimism and significant concerns regarding the safety and regulation of cannabinoid products, particularly those available without prescription.Methods: In recognition of the high interest and controversial nature of this subject, the meeting committee of the International Parkinson and Movement Disorders Society arranged for a talk on cannabis at the 2019 annual meeting's Controversies in Movement Disorders plenary session. This paper summarizes the highlights of this session.Results: The endocannabinoid system is strongly tied to motor function and dysfunction, with basic research suggesting several promising therapeutic targets related to cannabinoids for movement disorders. Clinical research on cannabinoids for motor and nonmotor symptoms in Parkinson's disease, Huntington's disease, Tourette's syndrome, dystonia, and other movement disorders to date are promising at best and inconclusive or negative at worst. Research in other populations suggest efficacy for common symptoms like pain. While social campaigns against recreational cannabinoid use focus on cognitive changes in adolescents, the long-term sequelae of regulated medical use in older adults with movement disorders is unknown. The overall risks of cannabinoids may be similar to other commonly used medications and include falls and apathy.Conclusion: Further research is greatly needed to better understand the actual clinical benefits and long-term side effects of medical cannabis products for movement disorders indications and populations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据